Evidence map›Paper›PMID 33802143›Full record

ReviewInternational journal of molecular sciences2021

Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial.

Bernardino Clavo, Gregorio Martínez-Sánchez, Francisco Rodríguez-Esparragón, Delvys Rodríguez-Abreu, Saray Galván, David Aguiar-Bujanda, Juan A Díaz-Garrido, Silvia Cañas, Laura B Torres-Mata, Himar Fabelo and 4 more

6 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04299893 phase2 / phase3recruitingnot on this map

Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)

TypeinterventionalSponsorBernardino Clavo, MD, PhDRan2020 to 2027Enrolled42ConditionsChemotherapy-induced Peripheral Neuropathy, Pain, Neuropathic, Pain SyndromeArmsOzone, Oxygen
NCT05417737 recruitingnot on this mapstarted 2022, after this paper: background citation

Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025. (EPOOzo)

Typeobservational_patient_registrySponsorBernardino Clavo, MD, PhDRan2022 to 2026Enrolled105ConditionsRadiation Toxicity, Chemotherapeutic Toxicity, Chemotherapy-induced Peripheral Neuropathy, Delayed Wound HealingArmsOzone therapy
NCT06706544 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Effectiveness and Cost-effectiveness of Ozone Treatment in Patients With Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (OzoParQT)

TypeinterventionalSponsorBernardino Clavo, MD, PhDRan2025 to 2030Enrolled42ConditionsChemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia, Numbness, TinglingArmsOzone therapy, Oxygen (placebo)
NCT06799351 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Gut Microbiome Profiles in Patients with Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial with Ozone OzoParQT (NCT06706544).

TypeinterventionalSponsorBernardino Clavo, MD, PhDRan2025 to 2030Enrolled42ConditionsChemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia, Numbness, TinglingArmsOzone therapy, Oxygen (placebo)
NCT06816095 recruitingnot on this mapstarted 2025, after this paper: background citation

Gene and Molecular Pathway Characterization of the Response to Ozone Treatment in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Radio-chemotherapy

TypeobservationalSponsorBernardino Clavo, MD, PhDRan2025 to 2027Enrolled40ConditionsChronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder, Radiotherapy Side Effects, Side Effect of Chemotherapy
NCT07325851 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029. Prospective Study EPOOzo-2.

Typeobservational_patient_registrySponsorBernardino Clavo, MD, PhDRan2026 to 2030Enrolled120ConditionsChemotherapy-Induced Peripheral Neuropathy, Radiation Toxicity, Chronic Pain, Delayed Wound HealingArmsOzone Therapy
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Bernardino ClavoResearch Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.ORCID 0000-0003-2522-1064
Gregorio Martínez-SánchezScientific Advisor, Freelance, 60126 Ancona, Italy.ORCID 0000-0002-6628-7388
Francisco Rodríguez-EsparragónResearch Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.ORCID 0000-0003-1663-3673
Delvys Rodríguez-AbreuMedical Oncology Department, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain.
Saray GalvánMedical Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.
David Aguiar-BujandaMedical Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-5623-9315
Juan A Díaz-GarridoPsychiatry Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.
Silvia CañasPsychiatry Department, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain.
Laura B Torres-MataResearch Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.
Himar FabeloInstitute for Applied Microelectronics (IUMA), University of Las Palmas de Gran Canaria (ULPGC), 35017 Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-9794-490X
Teresa TéllezResearch Network on Health Services in Chronic Diseases (REDISSEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Norberto Santana-RodríguezUniversitary Institute for Research in Biomedicine and Health (iUIBS), Molecular and Translational Pharmacology Group, University of Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain.
Leandro Fernández-PérezUniversitary Institute for Research in Biomedicine and Health (iUIBS), Molecular and Translational Pharmacology Group, University of Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain.ORCID 0000-0001-7802-465X
Gustavo Marrero-CallicoInstitute for Applied Microelectronics (IUMA), University of Las Palmas de Gran Canaria (ULPGC), 35017 Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-3784-5504
Hospital Universitario de Gran Canaria Doctor Negrín · ESUniversidad de Las Palmas de Gran Canaria · ESHospital Universitario Insular de Gran Canaria · ESInstituto de Salud Carlos III · ES

Funding

Colegio Oficial de Médicos de Las Palmas I42/20Fundación DISA 016/2019Fundación Española del Dolor BF1-19-13Instituto de Salud Carlos III PI 19/00458
6 · The paper itself

Abstract

(1) Background: Chemotherapy-induced peripheral neuropathy (CIPN) decreases the quality of life of patients and can lead to a dose reduction and/or the interruption of chemotherapy treatment, limiting its effectiveness. Potential pathophysiological mechanisms involved in the pathogenesis of CIPN include chronic oxidative stress and subsequent increase in free radicals and proinflammatory cytokines. Approaches for the treatment of CIPN are highly limited in their number and efficacy, although several antioxidant-based therapies have been tried. On the other hand, ozone therapy can induce an adaptive antioxidant and anti-inflammatory response, which could be potentially useful in the management of CIPN. (2) Methods: The aims of this works are: (a) to summarize the potential mechanisms that could induce CIPN by the most relevant drugs (platinum, taxanes, vinca alkaloids, and bortezomib), with particular focus on the role of oxidative stress; (b) to summarize the current situation of prophylactic and treatment approaches; (c) to describe the action mechanisms of ozone therapy to modify oxidative stress and inflammation with its potential repercussions for CIPN; (d) to describe related experimental and clinical reports with ozone therapy in chemo-induced neurologic symptoms and CIPN; and (e) to show the main details about an ongoing focused clinical trial. (3) Results: A wide background relating to the mechanisms of action and a small number of experimental and clinical reports suggest that ozone therapy could be useful to prevent or improve CIPN. (4) Conclusions: Currently, there are no clinically relevant approaches for the prevention and treatment of stablished CIPN. The potential role of ozone therapy in this syndrome merits further research. Randomized controlled trials are ongoing.

Indexed as

Anti-Inflammatory AgentsAntineoplastic AgentsAntioxidantsHumansNeoplasmsOxidative StressOzonePeripheral Nervous System DiseasesQuality of LifeRandomized Controlled Trials as TopicAnti-Inflammatory AgentsAntineoplastic AgentsAntioxidantsOzoneantioxidantscancer treatmentchemotherapy-induced peripheral neuropathychemotherapy-induced side effectschemotherapy-induced toxicityfree radicalsoxaliplatinoxidative stressozone therapyrandomized clinical trial

Identifiers

PMID33802143
PMCPMC7998838
OpenAlexW3134821719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.